Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy

Epilepsia

Volumn 55, Issue 8, 2014, Pages 1301-1306

  He, Xiao Jing ^a   Jian, Ling Yan ^a   He, Xiao Lin ^b   Tang, Man ^a   Wu, Yan ^a   Xu, Yuan Yuan ^a   Sun, Xiao Jie ^c   Zhao, Li Mei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG MEDICAL COLLEGE   (China)

^c Shenyang No7 People's Hospital   (China)

Author keywords

carbamazepine; EPHX1; SJS TEN

Indexed keywords

CARBAMAZEPINE; ABCB1 PROTEIN, HUMAN; ANTICONVULSIVE AGENT; BAG6 PROTEIN, HUMAN; CHAPERONE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; EPHX1 PROTEIN, HUMAN; EPOXIDE HYDROLASE; FAS ANTIGEN; FAS PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; MULTIDRUG RESISTANCE PROTEIN; SCN1A PROTEIN, HUMAN; SODIUM CHANNEL NAV1.1;

ABCB1 GENE; ANTICONVULSANT THERAPY; ARTICLE; BAG6 GENE; CHINA; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; CYP3A4 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERANCE; EPHX1 GENE; EPILEPSY; ETHNICITY; FAS GENE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MICA GENE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCN1A GENE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ADOLESCENT; ADULT; ALLELE; ASIAN; EPHX1; FEMALE; GENETIC POLYMORPHISM; GENETICS; MALE; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; SJS/TEN; YOUNG ADULT;

CARBAMAZEPINE; EPHX1; SJS/TEN;

ADOLESCENT; ADULT; ALLELES; ANTICONVULSANTS; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; CYTOCHROME P-450 CYP3A; EPILEPSY; EPOXIDE HYDROLASES; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, GENETIC; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 84905513580     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12655     Document Type: Article

References (28)

1. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson Syndrome. Nature 2004; 428: 486.
2. Zhang Y, Wang J, Zhao LM, et al. Strong association between HLA-B1502 and carbamazepine-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 2011; 67: 885-887.
3. Wang Q, Zhou JQ, Zhou LM, et al. Association between HLA-B1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 2011; 20: 446-448.
4. Wu XT, Hu FY, An DM, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B1502 allele among patients in central China. Epilepsy Behav 2010; 19: 405-408.
5. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson Syndrome is associated with HLA-B1502 allele in Thai Population. Epilepsia 2008; 49: 2087-2091.
6. Man CB, Kwan P, Baum L, et al. Association between HLA-B1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-1018.
7. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20: 1034-1041.
8. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143.
9. He XJ, Jian LY, He XL, et al. Assiciation between the HLA-B1502 allele and carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. Pharmacol Rep 2013; 65: 1256-1262.
10. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson Syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268.
11. Hung CC, Jen Tai J, Kao PJ, et al. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 2007; 8: 1151-1158.
12. Ru JL, He XJ, Qiu F, et al. Effects of ABCB1 polymorphisms on plasma carbamazepine concentration. J Clin Hosp Pharm 2012; 32: 820-824.
13. Bu HZ, Kang P, Deese AJ, et al. Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos 2005; 33: 1920-1924.
14. Yang CW, Hung SI, Juo CG, et al. HLA-B1502 bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson Syndrome. J Allergy Clin Immunol 2007; 120: 870-877.
15. Wu Y, Farrell J, Pirmohamed M, et al. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+, CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007; 119: 973-981.
16. Rozieres A, Vocanson M, Rodet K, et al. CD8+ T cells mediate skin allergy to amoxicillin in a mouse model. Allergy 2010; 65: 996-1003.
17. Niihara H, Kakamu T, Fujita Y, et al. HLA-A 31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol 2012; 39: 594-601.
18. Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson Syndrome. J Allergy Clin Immunol 2011; 128: 1266-1276.
19. Roujeau JC, Bricard G, Nicolas JF,. Drug-induced epidermal necrolysis: important new piece to end the puzzle. J Allergy Clin Immunol 2011; 128: 1277-1278.
20. Sachse C, Smith G, Wilkie MJ, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002; 23: 1839-1849.
21. Hassett C, Aicher L, Sidhu JS, et al. Human microsomal epoxide hydrolase: genetic polymorphism and function expression in vitro of amino acid variants. Hum Mol Genet 1994; 3: 421-428.
22. Hassett C, Lin J, Carty CL, et al. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 1997; 337: 275-283.
23. Maekawa K, Itoda M, Hanioka N, et al. Non-synonymous single nucleotide alterations in the microsomal epoxide hydrolase gene and their functional effects. Xenobiotica 2003; 33: 277-287.
24. Kitteringham NR, Davis C, Howard N, et al. (1996) Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10,11-epoxide and naphthalene. J Pharmacol Exp Ther 278: 1018-1027.
25. Nakajima Y, Saito Y, Shiseki K, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol 2005; 61: 25-34.
26. Puranik YG, Birnbaum AK, Marino SE, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 2013; 14: 34-45.
27. Liu YM, Luo J, Clive EB,. Adaptive immunity: based on the daul recognition responses of αβ-T cells. Self Nonself 2010; 1: 62-66.
28. Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118: 233-241.